Suplatast tosilate

Last updated on: 03.08.2022

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Suplatast tosilate (INN) is a Th2 cytokine inhibitor that can correct the imbalance in the Th1/Th2 immune response and shows clear clinical efficacy in bronchial asthma (BA).

The drug has been successfully used a few times to treat Kimura disease (Tamaoki J et al. 2000; Ueda Tet al. 2011).

Pharmacodynamics (Effect)This section has been translated automatically.

Suplatast tosilate is able to suppress the production of IgE, block the production of cytokines, and suppress allergy-related eosinophils.

Clinical studies on the efficacy of Suplatast have been conducted in Japan. Suplatast showed reasonable efficacy in the treatment of bronchial asthma, allergic rhinitis, and atopic dermatitis.

PreparationsThis section has been translated automatically.

Suplatast tosilate is not approved in the U.S. but is available in Japan as Tosilart® and IPD Capsules®.

LiteratureThis section has been translated automatically.

  1. Butterfield JH (2021) Successful Long-Term Control of the Syndrome of Episodic Angioedema With Eosinophilia (Gleich Syndrome) With Low-Dose Imatinib Mesylate and Prednisone. J Investig Med High Impact Case Rep 2324709620987691.
  2. Tamaoki J et al (2000) Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Tokyo Joshi-Idai Asthma Research Group. Lancet. 356: 273-278.
  3. Tsukagoshi H et al. (1998) Kimura's disease associated with bronchial asthma presenting eosinophilia and hyperimmunoglobulinemia E which were attenuated by suplatast tosilate. Internal Medicine 37: 1064-1067.
  4. Ueda Tet al. (2011) Kimura's disease treated with suplatast tosilate and loratadine. European Journal of Dermatology 21: 1020-1021.

Last updated on: 03.08.2022